EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses

Saad Hanif Abbasi iD, Jesper Hallas iD, Peter Bjødstrup Jensen, Hassan Al-Jasim, Anton Pottegård iD

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2025. Verfasst von Saad Hanif Abbasi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Pharmacoepidemiology, Anticoagulants, Practice Patterns, Physicians', Ischemic Stroke. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Danmarks Frie Forskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The type of prescriber typically fulfils the criteria for confounding, as it is associated both with the exposure (e.g., prescriber types may differ in their choice of first‐line treatment) and with the outcome (as different types of prescribers often treat patients with different disease severity). Additionally, the type of prescriber may correlate with other factors such as treatment adherence, surveillance or coding practices. Although information on the type of prescriber is often available in healthcare registries, it is very rarely employed to control for confounding in pharmacoepidemiological analyses. Here, we argue the potential value in adjusting for the prescriber type in pharmacoepidemiological studies. In an applied example, we conducted a cohort study using Danish healthcare registers of the risk of ischemic stroke associated with the use of direct oral anticoagulants (DOACs) compared to warfarin. We found a hazard ratio (HR) of 0.95 (95% CI: 0.90–1.01) for DOACs versus warfarin when adjusting only for age and sex. Further adjustment for prescriber type showed an effect of similar magnitude (HR 0.92; 95% CI: 0.87–0.98). However, interaction testing and stratified analyses confirmed prescriber type as an effect modifier. Future studies are needed to clarify the role of adjusting for prescriber type across other use cases and healthcare settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacoepidemiologyAnticoagulantsPractice Patterns, Physicians'Ischemic StrokeHumansMaleFemaleDenmarkWarfarinCohort StudiesRegistriesAgedMiddle Aged

Stichwörter der Autor:innen

confounder adjustmentconfoundingpharmacoepidemiologyprescriber settingprescriber type

Substanzen

AnticoagulantsWarfarin

Autor:innen und Institutionen

  • Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.

ORCID-Profile: Saad Hanif Abbasi, Jesper Hallas, Anton Pottegård

Förderung

  • Danmarks Frie Forskningsfond

Zitieren

APA

Abbasi, S. H., Hallas, J., Jensen, P. B., Al-Jasim, H., & Pottegård, A. (2025). Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70126

Vancouver

Abbasi SH, Hallas J, Jensen PB, Al-Jasim H, Pottegård A. Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70126

BibTeX
@article{Abbasi2025,
  author = {Abbasi, Saad Hanif and Hallas, Jesper and Jensen, Peter Bjødstrup and Al-Jasim, Hassan and Pottegård, Anton},
  title = {Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70126}
}
Kostenlos starten →